Gliomas: Volume 134
Volume 134
Published on 26. May 2016
Book
Hardback
464 pages
978-0-12-802997-8 (ISBN)
Description
Researchers' knowledge of gliomas continues to advance rapidly at both the basic and translational levels, and Gliomas provides a thorough overview of the evolving fields of tumor biology and clinical medicine as they relate to our understanding of brain tumors.
Gliomas reviews the current paradigms that underlie these fields, beginning with the molecular epidemiology of glioma susceptibility and prognosis through population-based science and genome-wide association studies. The book's discussion of imaging modalities extends beyond advances in anatomical imaging to include metabolic and physiological studies. This work provides thorough discussion of the clinical view of tumors, ranging from the presentation of the patient to surgical management, and covers all therapeutic options for patient care, including chemotherapy, targeted molecular therapies, immunotherapies, and even personalized approaches to impact the set of lesions. Additionally, the book discusses radiotherapy with regard to the many options available to treat patients using myriad fractionated techniques with various sources. Finally, Gliomas reviews issues specific to the quality of life for patients, and techniques for maximizing the effect of caregivers.
Edited and authored by premier researchers from around the world, Gliomas is a comprehensive reference for clinicians and researchers seeking the most up-to-date information on gliomas, and a guide to the best ways to effectively manage glioma patients and their care.
Gliomas reviews the current paradigms that underlie these fields, beginning with the molecular epidemiology of glioma susceptibility and prognosis through population-based science and genome-wide association studies. The book's discussion of imaging modalities extends beyond advances in anatomical imaging to include metabolic and physiological studies. This work provides thorough discussion of the clinical view of tumors, ranging from the presentation of the patient to surgical management, and covers all therapeutic options for patient care, including chemotherapy, targeted molecular therapies, immunotherapies, and even personalized approaches to impact the set of lesions. Additionally, the book discusses radiotherapy with regard to the many options available to treat patients using myriad fractionated techniques with various sources. Finally, Gliomas reviews issues specific to the quality of life for patients, and techniques for maximizing the effect of caregivers.
Edited and authored by premier researchers from around the world, Gliomas is a comprehensive reference for clinicians and researchers seeking the most up-to-date information on gliomas, and a guide to the best ways to effectively manage glioma patients and their care.
More details
Series
Language
English
Place of publication
United States
Target group
Professional and scholarly
Researchers, clinicians and advanced students in the fields of neurology, neuro-oncology, neurosurgery, radiation oncology, and clinical neuroscience.
Product notice
sewn/stitched
Cloth over boards
Dimensions
Height: 274 mm
Width: 195 mm
Thickness: 32 mm
Weight
1329 gr
ISBN-13
978-0-12-802997-8 (9780128029978)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Persons
Mitchel S. Berger M.D., F.A.C.S., F.A.A.N.S. is the Berthold and Belle N. Guggenhime Professor and Chairman of the Department of Neurological Surgery at the University of California, San Francisco (UCSF), and is an expert in the fields of neurosurgery and neuro-oncology. He also serves as Director of UCSF's Brain Tumor Research Center.
After graduating from Harvard University in 1974, Dr. Berger earned his medical degree from the University of Miami School of Medicine. He completed a clinical fellowship in neuro-oncology at UCSF, a fellowship in pediatric neurosurgery at the Hospital for Sick Children of the University of Toronto, and his neurosurgical residency at UCSF. In 1986, he became Assistant Professor of Neurosurgery at the University of Washington School of Medicine, after which he was named Associate Professor (1990) and Professor (1996).
Dr. Berger has clinical expertise in treating adult and pediatric brain and spinal cord tumors. He is a pioneer of intraoperative brain mapping - a technique used to avoid functional areas of the brain during surgical resection of a tumor. His work has enabled surgeons to perform more extensive resection of tumor with less chance of producing sensorimotor or language deficit.
Dr. Berger is a leader of translational research and is the Principal Investigator of the UCSF Brain Tumor Research Center's Specialized Program of Research Excellence in neuro-oncology, funded by the National Cancer Institute. His specific research interests lie in identifying molecular markers related to the progression and prognosis of glial tumors, as well as the development of small-molecule therapeutic agents that can be administered directly to the brain via convection-enhanced drug delivery.
During his distinguished career, Dr. Berger has served as President of the American Association of Neurological Surgeons, President of the Society of Neuro-Oncology, President of the North Pacific Society of Neurology, and Vice President of the Congress of Neurological Surgeons. He has also been a director of the American Board of Neurological Surgery and a member of the Board of Directors of the American Association of Neurological Surgeons. He is currently President of the American Academy of Neurological Surgery.
In 2009, Dr. Berger was awarded the prestigious Winn Prize by the Society for Neurological Surgery. He currently serves as a member of the National Football League Head, Neck and Spine Committee, focusing on retired players' issues and examining the consequences of repetitive head injury and concussion. He is also an active member of numerous professional organizations, including the American Organization for Cancer Research, the American College of Surgeons, and the World Federation of Neurosurgical Societies.
A prolific author, Dr. Berger has contributed over 500 scientific articles to peer-reviewed journals, has edited 6 textbooks, and has written over 80 chapters on various neurosurgical topics. He is currently on the editorial boards of several leading journals including Neuro-Oncology and Neurosurgery.
Dr. Michael Weller has been Chairman of the Department of Neurology at the University Hospital Zurich, Switzerland, since 2008. He qualified in medicine in Cologne, Germany, after completing his thesis on proliferative disorders of the retina. A postdoctoral fellowship at the Department of Clinical Immunology, University Hospital Zurich, Switzerland, followed where he identified death receptor targeting as a potential treatment strategy for malignant gliomas. In 2005, he was appointed Chairman of the Department of General Neurology at the University Hospital Tuebingen, Germany, where he had previously received his education in clinical neurology.Dr. Weller has received several awards in recognition of his contributions to cancer research, including the German Cancer Award in 2007. He served as Chairman of the Neuro-Oncology Group of the German Cancer Society from 2001-2008. He is the Chairman of the German Glioma Network of the German Cancer Council, joined the Executive Board of the European Association for Neuro-Oncology (EANO) in 2010 and was elected President of EANO for 2014-2016. He is also the Chairman of the Brain Tumor Group of the European Organization for Research and Treatment of Cancer (EORTC).Dr. Weller was involved in major practice-changing clinical trials including the registration trial for temozolomide in glioblastoma and served as PI on the NOA-03, NOA-04, NOA-08 and G-PCNSL-SG-1 trials in Germany and the DIRECTOR and ARTE trials in Switzerland . He is also a member of the editorial boards of the Journal of Neurochemistry, Journal of Neuro-Oncology, Brain and Glia, and he was the Associate Editor Europe of Neuro-Oncology from 2006-2013.Dr. Weller has co-authored more than 550 original publications in peer-reviewed journals, including The New England Journal of Medicine, Science, Nature, Nature Medicine, Lancet Oncology, PNAS, The Journal of Clinical Investigation, and The Journal of Clinical Oncology.
After graduating from Harvard University in 1974, Dr. Berger earned his medical degree from the University of Miami School of Medicine. He completed a clinical fellowship in neuro-oncology at UCSF, a fellowship in pediatric neurosurgery at the Hospital for Sick Children of the University of Toronto, and his neurosurgical residency at UCSF. In 1986, he became Assistant Professor of Neurosurgery at the University of Washington School of Medicine, after which he was named Associate Professor (1990) and Professor (1996).
Dr. Berger has clinical expertise in treating adult and pediatric brain and spinal cord tumors. He is a pioneer of intraoperative brain mapping - a technique used to avoid functional areas of the brain during surgical resection of a tumor. His work has enabled surgeons to perform more extensive resection of tumor with less chance of producing sensorimotor or language deficit.
Dr. Berger is a leader of translational research and is the Principal Investigator of the UCSF Brain Tumor Research Center's Specialized Program of Research Excellence in neuro-oncology, funded by the National Cancer Institute. His specific research interests lie in identifying molecular markers related to the progression and prognosis of glial tumors, as well as the development of small-molecule therapeutic agents that can be administered directly to the brain via convection-enhanced drug delivery.
During his distinguished career, Dr. Berger has served as President of the American Association of Neurological Surgeons, President of the Society of Neuro-Oncology, President of the North Pacific Society of Neurology, and Vice President of the Congress of Neurological Surgeons. He has also been a director of the American Board of Neurological Surgery and a member of the Board of Directors of the American Association of Neurological Surgeons. He is currently President of the American Academy of Neurological Surgery.
In 2009, Dr. Berger was awarded the prestigious Winn Prize by the Society for Neurological Surgery. He currently serves as a member of the National Football League Head, Neck and Spine Committee, focusing on retired players' issues and examining the consequences of repetitive head injury and concussion. He is also an active member of numerous professional organizations, including the American Organization for Cancer Research, the American College of Surgeons, and the World Federation of Neurosurgical Societies.
A prolific author, Dr. Berger has contributed over 500 scientific articles to peer-reviewed journals, has edited 6 textbooks, and has written over 80 chapters on various neurosurgical topics. He is currently on the editorial boards of several leading journals including Neuro-Oncology and Neurosurgery.
Dr. Michael Weller has been Chairman of the Department of Neurology at the University Hospital Zurich, Switzerland, since 2008. He qualified in medicine in Cologne, Germany, after completing his thesis on proliferative disorders of the retina. A postdoctoral fellowship at the Department of Clinical Immunology, University Hospital Zurich, Switzerland, followed where he identified death receptor targeting as a potential treatment strategy for malignant gliomas. In 2005, he was appointed Chairman of the Department of General Neurology at the University Hospital Tuebingen, Germany, where he had previously received his education in clinical neurology.Dr. Weller has received several awards in recognition of his contributions to cancer research, including the German Cancer Award in 2007. He served as Chairman of the Neuro-Oncology Group of the German Cancer Society from 2001-2008. He is the Chairman of the German Glioma Network of the German Cancer Council, joined the Executive Board of the European Association for Neuro-Oncology (EANO) in 2010 and was elected President of EANO for 2014-2016. He is also the Chairman of the Brain Tumor Group of the European Organization for Research and Treatment of Cancer (EORTC).Dr. Weller was involved in major practice-changing clinical trials including the registration trial for temozolomide in glioblastoma and served as PI on the NOA-03, NOA-04, NOA-08 and G-PCNSL-SG-1 trials in Germany and the DIRECTOR and ARTE trials in Switzerland . He is also a member of the editorial boards of the Journal of Neurochemistry, Journal of Neuro-Oncology, Brain and Glia, and he was the Associate Editor Europe of Neuro-Oncology from 2006-2013.Dr. Weller has co-authored more than 550 original publications in peer-reviewed journals, including The New England Journal of Medicine, Science, Nature, Nature Medicine, Lancet Oncology, PNAS, The Journal of Clinical Investigation, and The Journal of Clinical Oncology.
Volume editor
Kathleen M. Plant Distinguished Professor and Chairman, Department of Neurological Surgery; Director, Neurological Surgery Research Centers and Brain Tumor Research Center; Director, Brain Tumor Surgery Program, University of California, San Francisco, San Francisco, CA
Department of Neurology, University Hospital Zurich, Zurich, Switzerland
Content
Section 1 Diagnosis and treatment
1. Epidemiology
2. Presenting signs and symptoms in brain tumors
3. Neuroimaging
4. Surgical approaches for the gliomas
5. Histological classification of gliomas
6. Molecular classification of gliomas
7. Next generation molecular diagnostics
8. Principles of radiation therapy
9. Principles of pharmacotherapy
10. Principles of immunotherapy
11. Experimental therapies: gene therapies and oncolytic viruses
Section 2 Complications and symptomatic management
12. Complications of glioma surgery
13. Complications from radiotherapy
14. Complications from pharmacotherapy
15. Vascular complications in glioma patients
16. Epilepsy and brain tumors
17. Rehabilitation of patients with glioma
18. Psycho-oncology
19. Palliative care at the end of life in glioma patients
Section 3 Disease specific chapters
20. Pilocytic astrocytomas
21. Astrocytic gliomas (WHO Grades II and III)
22. Low grade and anaplastic oligodendroglioma
23. Glioblastoma
24. Rare glial tumors
25. Ependymoma - A heterogeneous tumor of uncertain origin and limited therapeutic options
1. Epidemiology
2. Presenting signs and symptoms in brain tumors
3. Neuroimaging
4. Surgical approaches for the gliomas
5. Histological classification of gliomas
6. Molecular classification of gliomas
7. Next generation molecular diagnostics
8. Principles of radiation therapy
9. Principles of pharmacotherapy
10. Principles of immunotherapy
11. Experimental therapies: gene therapies and oncolytic viruses
Section 2 Complications and symptomatic management
12. Complications of glioma surgery
13. Complications from radiotherapy
14. Complications from pharmacotherapy
15. Vascular complications in glioma patients
16. Epilepsy and brain tumors
17. Rehabilitation of patients with glioma
18. Psycho-oncology
19. Palliative care at the end of life in glioma patients
Section 3 Disease specific chapters
20. Pilocytic astrocytomas
21. Astrocytic gliomas (WHO Grades II and III)
22. Low grade and anaplastic oligodendroglioma
23. Glioblastoma
24. Rare glial tumors
25. Ependymoma - A heterogeneous tumor of uncertain origin and limited therapeutic options